You are here: Industry Insights > PTC

News List

PTC Therapeutics Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome firstwordpharma
August 24, 2021
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS)
Evrysdi Trial Demonstrates Improvement of Motor Function in SMA Patients americanpharmaceuticalreview
March 22, 2021
PTC Therapeutics announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) at the 2021 Muscular Dystrophy Association (MDA) Virtual and ...
CHMP Adopts Positive Opinion for Evrysdi for Spinal Muscular Atrophy americanpharmaceuticalreview
March 03, 2021
PTC Therapeutics announced the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months and ...
PTC Therapeutics Initiates Second Stage of FITE19 Trial Evaluating PTC299 for COVID-19 americanpharmaceuticalreview
February 19, 2021
PTC Therapeutics announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19 patients.
PTC Therapeutics Expands in New Jersey contractpharma
August 06, 2019
Secures BMS biologics facility to support gene therapy production.
PTC Therapeutics, Odylia Therapeutics Enter Gene Therapy Alliance contractpharma
July 03, 2019
Expands PTC's gene therapy portfolio to rare ophthalmic diseases .
PTC Provides Update on Translarna™ Application for Label Expansion americanpharmaceuticalreview
July 01, 2019
PTC Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has completed their review of ...
PTC Therapeutics Receives FDA Approval for the Expansion of the Emflaza (deflazacort) Labeling to Include Patients 2-5 Years of Age drugs
June 11, 2019
PTC Therapeutics Receives FDA Approval for the Expansion of the Emflaza (deflazacort) Labeling to Include Patients 2-5 Years of Age.
PTC gets FDA nod for the expansion of the EMFLAZA® labeling biospectrumasia
June 10, 2019
Emflaza is the only approved treatment for all patients two and over living with Duchenne muscular dystrophy
PTC Therapeutics Appoints CFO contractpharma
June 04, 2019
Ms. Hill joined the company in November 2013 and was most recently senior vice president and head of Investor Relations.

Previous page 1 2 Next page